Research Paper
Assessing the interest to participate in a dengue vaccine efficacy trial among residents of Puerto Rico
Purchase or Subscribe
Volume 8, Issue 7 July 2012
Pages 905 - 915
http://dx.doi.org/10.4161/hv.20056
Keywords: Dengue vaccine, children vaccine trials, dengue placebo-controlled trials, dengue prevention, dengue qualitative research
Authors: Carmen L. Pérez Guerra, Rosa Rodríguez-Acosta, Eunice Soto-Gómez, Emily Zielinski-Gutierrez, Marisol Peña-Orellana, Luis Santiago, Reinaldo Rivera, R. Rhode Cruz, Viani Ramírez, Kay Tomashek and Gustavo Dayan
View affiliations Hide affiliations
- Carmen L. Pérez Guerra
-
Corresponding author: cnp8@cdc.gov
Dengue Branch, Division of Vector Borne Diseases; National Center for Emerging and Zoonotic Infectious Diseases; Centers for Disease Control and Prevention; San Juan, Puerto Rico
- Rosa Rodríguez-Acosta
-
Dengue Branch, Division of Vector Borne Diseases; National Center for Emerging and Zoonotic Infectious Diseases; Centers for Disease Control and Prevention; San Juan, Puerto Rico
- Eunice Soto-Gómez
-
Dengue Branch, Division of Vector Borne Diseases; National Center for Emerging and Zoonotic Infectious Diseases; Centers for Disease Control and Prevention; San Juan, Puerto Rico
- Emily Zielinski-Gutierrez
-
Division of Vector Borne Diseases; National Center for Emerging and Zoonotic Infectious Diseases; Centers for Disease Control and Prevention; Fort Collins, Colorado USA
- Marisol Peña-Orellana
-
Dengue Branch, Division of Vector Borne Diseases; National Center for Emerging and Zoonotic Infectious Diseases; Centers for Disease Control and Prevention; San Juan, Puerto Rico; Center for Preparedness in Public Health; School of Public Health; Medical Sciences Campus; University of Puerto Rico; Río Piedras, Puerto Rico
- Luis Santiago
-
Dengue Branch, Division of Vector Borne Diseases; National Center for Emerging and Zoonotic Infectious Diseases; Centers for Disease Control and Prevention; San Juan, Puerto Rico
- Reinaldo Rivera
-
Dengue Branch, Division of Vector Borne Diseases; National Center for Emerging and Zoonotic Infectious Diseases; Centers for Disease Control and Prevention; San Juan, Puerto Rico
- R. Rhode Cruz
-
Dengue Branch, Division of Vector Borne Diseases; National Center for Emerging and Zoonotic Infectious Diseases; Centers for Disease Control and Prevention; San Juan, Puerto Rico
- Viani Ramírez
-
Dengue Branch, Division of Vector Borne Diseases; National Center for Emerging and Zoonotic Infectious Diseases; Centers for Disease Control and Prevention; San Juan, Puerto Rico; Georgia Violent Death Reporting System (GVDRS); Chronic Disease, Healthy Behaviors and Injury; Epidemiology Section; Georgia Department of Public Health; Georgia, USA
- Kay Tomashek
-
Dengue Branch, Division of Vector Borne Diseases; National Center for Emerging and Zoonotic Infectious Diseases; Centers for Disease Control and Prevention; San Juan, Puerto Rico
- Gustavo Dayan
-
Clinical Development; Sanofi Pasteur; Swiftwater, Pennsylvania USA
Abstract:
Dengue, endemic in Puerto Rico, is a major public health problem. Vaccines are thought the best means to prevent dengue because vector control alone has been largely ineffective. We implemented qualitative studies in 2006 and 2010 to determine the acceptability of conducting placebo-controlled dengue vaccine efficacy trials in Puerto Rican children. Key informant interviews and focus groups with parents and children were conducted in municipalities with high dengue incidence. We used structured open-ended questions to determine motivators and attitudes regarding vaccine trial participation. Knowledge about dengue risk and prevention, and knowledge, attitudes, and beliefs regarding vaccines and vaccine trials were assessed. Using grounded theory, we conducted content analysis and established categories and sub-categories of participant responses. All participants were knowledgeable about dengue prevention and perceived children as most affected age groups. Participants were aware of vaccines benefits and they thought a vaccine could prevent dengue. However, most would not allow their children to participate in a placebo-controlled vaccine trial. Barriers included lack of trust in new vaccines and vaccine trial procedures; fear of developing dengue or side effects from the vaccine and lack of information about candidate dengue vaccines. Participants thought information, including results of previous trials might overcome barriers to participation. Motivators for participation were altruism, protection from dengue, free medical attention, and compensation for transportation and participation. Parents would consider children participation if accurate vaccine trial information is provided.
Received: January 4, 2012; Accepted: March 18, 2012; Published Online: July 1, 2012
Preview: